|
Financial Instruments (Details) (USD $)
In Thousands, except Share data, unless otherwise specified |
3 Months Ended | 6 Months Ended | 3 Months Ended | 6 Months Ended | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Sep. 30, 2013
|
Sep. 30, 2012
|
Sep. 30, 2013
|
Sep. 30, 2012
|
Jun. 30, 2013
Contract
|
Mar. 31, 2013
|
Jul. 12, 2012
|
Sep. 30, 2013
Nano Vibronix [Member]
|
Sep. 30, 2013
Nano Vibronix [Member]
|
Sep. 30, 2013
Nano Vibronix [Member]
Convertible Promissory Note [Member]
|
Nov. 22, 2011
Nano Vibronix [Member]
Convertible Promissory Note [Member]
|
Sep. 30, 2013
Liability Warrants Having Exercise Price 30 [Member]
|
||||
| Financial Instruments [Abstract] | |||||||||||||||
| Foreign currency transaction gains and (losses) | $ 0 | $ 0 | |||||||||||||
| Number of open foreign exchange contracts | 0 | ||||||||||||||
| Class of Warrant or Right [Line Items] | |||||||||||||||
| Warrants outstanding (in shares) | 285,454 | 285,454 | 8,288 | ||||||||||||
| Exercise price of warrants outstanding (in dollars per share) | $ 30.00 | ||||||||||||||
| Non cash gains on warrants | 10 | 3 | |||||||||||||
| Note receivable - CollabRx | 0 | 0 | |||||||||||||
| Debt extinguishment as a consideration of acquisition | 300 | ||||||||||||||
| Promissory note liability assumed as a purchase price of acquisition | 500 | 500 | 500 | ||||||||||||
| Investment [Line Items] | |||||||||||||||
| Strategic investment | 362 | 362 | 345 | [1] | 300 | ||||||||||
| Interest rate on convertible promissory note (in hundredths) | 10.00% | ||||||||||||||
| Maturity date of convertible promissory note | Nov. 15, 2014 | Nov. 15, 2014 | |||||||||||||
| Convertible preferred stock | $ 3,000 | $ 3,000 | |||||||||||||
| Conversion price (in dollars per share) | $ 0.284 | $ 0.284 | |||||||||||||
|
|||||||||||||||